Objective: Determine if autoantibody titer magnitude and variability predict glucose abnormalities in subjects at risk for type 1 diabetes.
| INTRODUCTION
Type 1 diabetes is a prototypical autoimmune disease with an asymptomatic prodrome characterized by the development of autoantibodies against islet antigens and the progressive loss of β-cell function. 1 There are 5 autoantibodies associated with type 1 diabetes: islet cell cytoplasmic autoantibodies (ICA), insulin autoantibodies (IAA), islet cell cytoplasmic 512 autoantibodies (ICA512), glutamic acid decarboxylase antibodies (GAD65), and zinc transporter 8 antibodies (ZnT8). Multiple longitudinal studies have confirmed that increasing numbers of circulating autoantibodies are a strong predictor of progression to diabetes. [2] [3] [4] Studies have been less consistent, however, when evaluating the impact of the levels or titers of individual autoantibodies on progression to clinical disease.
Early data on the first autoantibody assay, islet cell antigen (ICA),
showed that quantity of autoantibody (ie, titer), not just the presence of autoantibody, predicted development of type 1 diabetes. 5 With the development of additional autoantibody assays, such as GAD65
and ICA512, analyses of large prevention cohorts like the Diabetes Prevention Trial (DPT-1) demonstrated that titers fluctuate in the atrisk population. 6 In the DPT-1, at-risk subjects who were ICA+ were † Members of the Type 1 Diabetes TrialNet Study Group are listed in the Appendices S1 and S2 (Supporting Information).
enrolled to receive either oral insulin or parenteral insulin. In those that progressed to diabetes, it was observed that baseline GAD65 titers decreased while IA2 (now referred to as ICA512) titers increased at the time of diagnosis. 6 This was true even when subjects were positive for both GAD65 and IA2 at baseline. A comparable analysis of non-progressors was not reported. Additional analysis of DPT-1 subjects with abnormal first phase insulin release (FPIR) demonstrated that higher titers of ICA512 and IAA correlated negatively, albeit weakly, with FPIR while titers of GAD65 did not.
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A cross-sectional study by Bonifacio and Ziegler on a German cohort of first-degree relatives also demonstrated that autoantibody titers correlated with diabetes progression over 10 years, similar to the DPT-1. They observed that those with the higher titers of IAA and IA2 were more likely to develop type 1 diabetes but GAD65 titer was not predictive. 8 However, in the longitudinal Diabetes Autoimmunity Study in the Young (DAISY) study, subjects with higher autoantibody titers were more likely to remain positive but titer elevation did not appear to contribute to progression of disease. We analyzed subjects who were positive for at least 2 autoantibodies at some point during their follow-up. This population was selected for analysis given the higher rate of progression to abnormal glucose tolerance tests in subjects with >1 autoantibody. 15 Analysis of the predictive capacity of titers was limited to GAD65, ICA512, and IAA. ZnT8 and the so-called harmonized GAD65 and ICA512 assays began to be collected (in addition to standard GAD65, ICA512, and IAA) several years into the Pathway to Prevention study, limiting the number of measurements per subject for these newer assays. Positivity to ZnT8 was used, however, to meet criteria for analysis (ie, ≥2 autoantibodies).
The average titer score was calculated by averaging all of an individual's titer scores (regardless of being designated positive or negative by the reference lab) during their follow-up. Similarly, cumulative standard deviations were calculated as the standard deviation of an individual's titer scores during their follow-up in the study. All subjects or their parent/guardian-provided informed consent prior to study enrollment. Children provided assent as required by the local institution.
| Statistics
All statistical analysis was carried out in R. The multivariate proportional odds model utilized the R ordinal package developed by Christensen. 16 The matched pairs data were analyzed using Wilcoxon rank tests. 17 
| RESULTS
A total of 826 subjects with ≥2 autoantibodies were available for analysis of whom 57% were female. The mean age of entry and duration of follow-up were 12 AE 14.1 and 5.1 AE 1.7 years, respectively.
The mean number of autoantibody measurements per subject with standard deviations for GAD65, ICA512, and mIAA were 6.3 AE 3.6, 6.0 AE 3.4, and 6.5 AE 2.4, respectively. Of the 826 subjects, 46 subjects only had 1 observation with an OGTT and 2 subjects were missing glucose data from their OGTT tests. Therefore, a total of 778 subjects were analyzed.
We first determined an individual's mean titer level (referred to as the average titer score) for each autoantibody for the duration of the study by averaging their autoantibody titer results. All titer levels, regardless of "positive" or "negative" status, were included in the cal- and GAD65 correlated with a greater dysglycemia (ie, an impaired or (Table 1) . When evaluating the difference between these 2 time points, we found that t ICA512 titer levels significantly increased in the case group over time compared with the control groups ( Table 2 ). In contrast, titer levels for GAD65 and mIAA did not change significantly in either cases or controls between the initial value and the follow-up OGTT. 19 The lack of association of IAA titer with abnormal glucose tolerance does not conflict with published data regarding the importance of IAA in development of type 1 diabetes. 20 Our study looked at a different population namely those with multiple autoantibodies at some point during their follow-up in the TrialNet Pathway to Prevention study. Unlike other studies, our cohort was not followed at birth so it is possible that the development of IAA in the very young might be especially important as has been published. 20 Finally, given our observations of increased 
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In conclusion, we demonstrate that autoantibody titers, particularly of ICA512, correlate with abnormal OGTT results in subjects at risk for disease. Future studies will investigate the utility of changes in autoantibody titers to predict outcomes in prevention studies of type 1 diabetes.
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